Association of serum gastric inhibitory polypeptide and pancreatic polypeptide levels with prolonged esophageal acid exposure time in refractory gastroesophageal reflux disease.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
entrez:
7
6
2019
pubmed:
7
6
2019
medline:
18
6
2019
Statut:
ppublish
Résumé
Acid exposure time (AET) prolongation plays an important role in the pathogenesis of gastroesophageal reflux disease (GERD). Gastric inhibitory polypeptide (GIP) and pancreatic polypeptide (PP) participate in the regulation of gastric acid secretion, blood glucose and lipid levels, and food intake. In this study, we evaluated the serum GIP and PP levels in refractory GERD patients and analyzed their metabolic and motility characteristics. Seventy-three refractory GERD patients were enrolled in this study from September 2015 to September 2017. We investigated the clinical characteristics, severity, and duration of GERD symptoms. High-resolution manometry and 24 hours impedance-pH monitoring were performed to assess esophageal motility and reflux parameters. The patients were divided into the AET- group (AET <4.2%) and AET+ group (AET >4.2%). GIP and PP levels were determined in all subjects and their associations with other parameters evaluated. Age and GERDQ score were significantly higher (P < .05) and acid reflux and heartburn more frequent in the AET+ group than in the AET- group. The contraction front velocity was increased in the AET- group, while there was no significant difference in the distal contraction integral, peristalsis interruption, distal latency, or resting pressures of the lower and upper esophageal sphincters between the 2 groups (P > .05). The serum levels of GIP (P = .003) and PP (P = .012) were significantly increased in the AET+ group. Increased GIP and PP levels were associated with abnormal upright AET (correlation coefficients 0.307 and 0.233, P = .008 and P = .047). There was a positive correlation between GIP and triglyceride levels (correlation coefficient 0.279, P = .017). The serum levels of GIP and PP in refractory GERD patients with prolongation of AET are significantly elevated, mainly in the upright position.
Sections du résumé
BACKGROUND
BACKGROUND
Acid exposure time (AET) prolongation plays an important role in the pathogenesis of gastroesophageal reflux disease (GERD). Gastric inhibitory polypeptide (GIP) and pancreatic polypeptide (PP) participate in the regulation of gastric acid secretion, blood glucose and lipid levels, and food intake. In this study, we evaluated the serum GIP and PP levels in refractory GERD patients and analyzed their metabolic and motility characteristics.
METHODS
METHODS
Seventy-three refractory GERD patients were enrolled in this study from September 2015 to September 2017. We investigated the clinical characteristics, severity, and duration of GERD symptoms. High-resolution manometry and 24 hours impedance-pH monitoring were performed to assess esophageal motility and reflux parameters. The patients were divided into the AET- group (AET <4.2%) and AET+ group (AET >4.2%). GIP and PP levels were determined in all subjects and their associations with other parameters evaluated.
RESULTS
RESULTS
Age and GERDQ score were significantly higher (P < .05) and acid reflux and heartburn more frequent in the AET+ group than in the AET- group. The contraction front velocity was increased in the AET- group, while there was no significant difference in the distal contraction integral, peristalsis interruption, distal latency, or resting pressures of the lower and upper esophageal sphincters between the 2 groups (P > .05). The serum levels of GIP (P = .003) and PP (P = .012) were significantly increased in the AET+ group. Increased GIP and PP levels were associated with abnormal upright AET (correlation coefficients 0.307 and 0.233, P = .008 and P = .047). There was a positive correlation between GIP and triglyceride levels (correlation coefficient 0.279, P = .017).
CONCLUSION
CONCLUSIONS
The serum levels of GIP and PP in refractory GERD patients with prolongation of AET are significantly elevated, mainly in the upright position.
Identifiants
pubmed: 31169725
doi: 10.1097/MD.0000000000015965
pii: 00005792-201906070-00059
pmc: PMC6571252
doi:
Substances chimiques
Gastric Inhibitory Polypeptide
59392-49-3
Pancreatic Polypeptide
59763-91-6
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15965Références
World J Gastroenterol. 2008 Feb 7;14(5):709-12
pubmed: 18205259
Auton Neurosci. 2006 Dec 30;130(1-2):1-5
pubmed: 16798102
Gastroenterology. 2001 Jun;120(7):1588-98
pubmed: 11375941
J Diabetes Complications. 2011 Sep-Oct;25(5):325-8
pubmed: 21813291
Am J Gastroenterol. 2009 Mar;104(3):553-9
pubmed: 19223881
Neurogastroenterol Motil. 2002 Dec;14(6):647-55
pubmed: 12464087
Dis Esophagus. 2016 Jul;29(5):484-9
pubmed: 25873206
Eur J Gastroenterol Hepatol. 1998 Feb;10(2):119-24
pubmed: 9581986
Digestion. 2017;95(3):221-228
pubmed: 28343226
Am J Physiol Endocrinol Metab. 2015 Mar 1;308(5):E414-25
pubmed: 25537494
Gastroenterology. 2007 Dec;133(6):1796-805
pubmed: 18054552
Am J Gastroenterol. 2001 Mar;96(3):647-55
pubmed: 11280529
Gut. 2006 Mar;55(3):313-8
pubmed: 16120760
Lancet. 1977 Jan 22;1(8004):161-3
pubmed: 64696
Biochem J. 1980 Apr 15;188(1):193-9
pubmed: 6996676
Neurogastroenterol Motil. 2015 Feb;27(2):160-74
pubmed: 25469569
Best Pract Res Clin Gastroenterol. 2013 Jun;27(3):353-64
pubmed: 23998974
Best Pract Res Clin Gastroenterol. 2004;18 Suppl:31-8
pubmed: 15588793
Gut. 2014 Jun;63(6):871-80
pubmed: 23853213
Dig Dis Sci. 1997 Sep;42(9):1859-65
pubmed: 9331148
Am J Gastroenterol. 2001 Sep;96(9):2569-74
pubmed: 11569677
Am J Gastroenterol. 2003 Sep;98(9):1940-4
pubmed: 14499769
Gut. 2004 Jul;53(7):1024-31
pubmed: 15194656
Endocr Rev. 1995 Jun;16(3):390-410
pubmed: 7671853
Aliment Pharmacol Ther. 2013 Mar;37(5):564-72
pubmed: 23289763
Aliment Pharmacol Ther. 2005 Apr 1;21(7):821-7
pubmed: 15801917
J Physiol Pharmacol. 2011 Dec;62(6):591-9
pubmed: 22314561
J Nutr. 1995 Feb;125(2):183-8
pubmed: 7861244